Ocular Therapeutix, Inc.

Contributing Author

Recent Articles by Ocular Therapeutix, Inc.

4 hours	Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OCUL GlobeNewswire
Feb-24	Ocular Therapeutix to Participate in March Investor Conferences OCUL +6.48% GlobeNewswire
Feb-23	Ocular Therapeutix to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations OCUL +8.10% GlobeNewswire
Feb-17	Ocular Therapeutix Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD OCUL -21.28% GlobeNewswire
Feb-13	Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 OCUL GlobeNewswire
Feb-06	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) OCUL GlobeNewswire
Feb-05	Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights OCUL GlobeNewswire
Jan-23	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) OCUL -7.64% OCUL +6.04% GlobeNewswire
Jan-21	Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer OCUL GlobeNewswire
Dec-08	Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD OCUL +28.06% GlobeNewswire
Dec-05	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) OCUL GlobeNewswire
Nov-24	Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI in NPDR OCUL GlobeNewswire
Nov-12	Ocular Therapeutix to Participate in November and December Investor Conferences OCUL GlobeNewswire
Nov-07	Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) OCUL GlobeNewswire
Nov-04	Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights OCUL GlobeNewswire
Nov-04	Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R OCUL GlobeNewswire
Oct-28	Ocular Therapeutix to Report Third Quarter 2025 Financial Results on November 4, 2025 OCUL GlobeNewswire
Oct-07	Ocular Therapeutix to Participate in Upcoming Scientific Conferences OCUL +5.01% GlobeNewswire
Sep-30	Ocular Therapeutix Announces Pricing of Underwritten Offering of Common Stock OCUL -6.70% GlobeNewswire
Sep-30	Ocular Therapeutix Investor Day to Highlight Exceptional AXPAXLI Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint OCUL -6.70% GlobeNewswire
Sep-08	Ocular Therapeutix to Host Investor Day on September 30, 2025 OCUL -6.54% GlobeNewswire
Aug-27	Ocular Therapeutix to Participate in September Investor and Scientific Conferences OCUL GlobeNewswire
Aug-12	Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI in NPDR OCUL GlobeNewswire
Aug-05	Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights OCUL GlobeNewswire
Jul-29	Ocular Therapeutix to Report Second Quarter 2025 Financial Results on August 5, 2025 OCUL GlobeNewswire
Jul-22	Ocular Therapeutix to Participate in Upcoming Scientific Conferences OCUL GlobeNewswire
Jun-26	Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company OCUL GlobeNewswire
Jun-16	Ocular Therapeutix to Participate in Clinical Trials at the Summit (CTS) 2025 OCUL GlobeNewswire
May-28	Ocular Therapeutix To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI in Wet Age-Related Macular Degeneration OCUL +13.69% GlobeNewswire
May-14	Ocular Therapeutix to Participate in Upcoming Investor Conferences OCUL GlobeNewswire
May-05	Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights OCUL -12.16% GlobeNewswire

Ocular Therapeutix, Inc.

Recent Articles by Ocular Therapeutix, Inc.

Upgrade your FINVIZ experience